Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

References

• EstellerMEpigenetics in cancerN Engl J Med2008358111148115918337604
   PubMed Web of Science ®Google Scholar
• KennedyRDQuinnJEJohnstonPGHarkinDPBRCA1: mechanisms of inactivation and implications for management of patientsLancet200236093381007101412383682
   PubMed Web of Science ®Google Scholar
• BirgisdottirVStefanssonOABodvarsdottirSKHilmarsdottirHJonassonJGEyfjordJEEpigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancerBreast Cancer Res200684R3816846527
   PubMed Web of Science ®Google Scholar
• BalmañaJDíezORubioITCardosoFESMO Guidelines Working GroupBRCA in breast cancer: ESMO clinical practice guidelinesAnn Oncol201122Suppl 6vi31vi3421908500
   PubMedGoogle Scholar
• SenkusEKyriakidesSOhnoSESMO Guidelines CommitteePrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• HuoberJvon MinckwitzGDenkertCEffect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyBreast Cancer Res Treat2010124113314020697801
   PubMed Web of Science ®Google Scholar
• GerberBLoiblSEidtmannHGerman Breast Group InvestigatorsNeoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)Ann Oncol201324122978298424136883
   PubMed Web of Science ®Google Scholar
• YardleyDAShipleyDLPeacockNWPhase I/II trial of neo-adjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancerBreast Cancer Res Treat2015152355756726155975
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• GucalpATolaneySIsakoffSJTranslational Breast Cancer Research Consortium (TBCRC 011)Phase II Trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res201319195505551223965901
   PubMed Web of Science ®Google Scholar
• TrainaTAMillerKYardleyDAResults from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)J Clin Oncol201533Suppl 15 abstract 1003
   PubMed Web of Science ®Google Scholar
• NabholtzJMAbrialCMouret-ReynierMAMulticentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactAnn Oncol20142581570157724827135
   PubMed Web of Science ®Google Scholar
• HafftyBGYangQReissMLocoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancerJ Clin Oncol200624365652565717116942
   PubMed Web of Science ®Google Scholar
• D’AndreaADGrompeMThe Fanconi anaemia/BRCA pathwayNat Rev Cancer200331233412509764
   PubMed Web of Science ®Google Scholar
• ByrskiTHuzarskiTDentRPathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Res Treat2014147240140525129345
   PubMed Web of Science ®Google Scholar
• WangCZhangJWangYPrevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancerAnn Oncol201526352352825480878
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• SilverDPRichardsonALEklundACEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerJ Clin Oncol20102871145115320100965
   PubMed Web of Science ®Google Scholar
• ChabalierCLamareCRaccaCPrivatMValetteALarminatFBRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistanceCell Cycle2006591001100716639080
   PubMed Web of Science ®Google Scholar
• TelliMLTimmsKMReidJHomologous recombination deficiency (HRD) as a predictive biomarkers of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancerCancer Res2016764 Suppl P3-07-12
   Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• GluzONitzULiedtkeCComparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trialCancer Res2016764 Suppl Abstract nr S6-07
   Google Scholar
• HerbstRSReview of epidermal growth factor receptor biologyInt J Radiat Oncol Biol Phys2004592 Suppl2126
   PubMed Web of Science ®Google Scholar
• ZhangHBerezovAWangQErbB receptors: from oncogenes to targeted cancer therapiesJ Clin Invest200711782051205817671639
   PubMed Web of Science ®Google Scholar
• SiziopikouKPCobleighMThe basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapiesBreast200716110410717097880
   PubMed Web of Science ®Google Scholar
• BidardFCConfortiRBouletTMichielsSDelalogeSAndréFDoes triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancersAnn Oncol20071871285128617675400
   PubMed Web of Science ®Google Scholar
• NogiHKobayashiTSuzukiMEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancerOncol Rep200921241341719148516
   PubMed Web of Science ®Google Scholar
• LiuDHeJYuanZEGFR expression correlates with decreased disease-free survival in triple negative breast cancer: a retrospective analysis based on a tissue microarrayMed Oncol201229240140521264531
   PubMed Web of Science ®Google Scholar
• FerraroDAGaboritNMaronRInhibition of triple-negative breast cancer models by combinations of antibodies to EGFRProc Natl Acad Sci U S A201311051815182023319610
   PubMed Web of Science ®Google Scholar
• DisisMLStantonSETriple-negative breast cancer: immune modulation as the new treatment paradigmAm Soc Clin Oncol Educ Book2015e25e3025993181
   PubMedGoogle Scholar
• García-TeijidoPCabalMLFernándezIPPérezYFTumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targetingClin Med Insights Oncol201610Suppl 1313927081325
   PubMedGoogle Scholar
• DenkertCLoiblSNoskeATumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancerJ Clin Oncol201028110511319917869
   PubMed Web of Science ®Google Scholar
• DieciMVCriscitielloCGoubarAPrognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyAnn Oncol201425361161824401929
   PubMed Web of Science ®Google Scholar
• VinayakSGrayRJAdamsSAssociation of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105J Clin Oncol201432Suppl 15 abstract 1000
   Web of Science ®Google Scholar
• SalgadoRDenkertCDemariaSInternational TILs Working Group 2014The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014Ann Oncol201526225927125214542
   PubMed Web of Science ®Google Scholar
• PruneriGVingianiABagnardiVClinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerAnn Oncol201627224925626598540
   PubMed Web of Science ®Google Scholar
• LoiSMichielsSSalgadoRTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnn Oncol20142581544155024608200
   PubMed Web of Science ®Google Scholar
• AdamsSGrayRJDemariaSPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol201432272959296625071121
   PubMed Web of Science ®Google Scholar
• Cimino-MathewsAFooteJBEmensLAImmune targeting in breast cancerOncology (Williston Park)201529537538525979549
   PubMed Web of Science ®Google Scholar
• DenkertCvon MinckwitzGDarb-EsfahaniSEvaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy – a metaanalysis of 3771 patientsCancer Res2017774 Suppl Abstract nr S1-09
   Google Scholar
• ZitvogelLApetohLGhiringhelliFAndréFTesniereAKroemerGThe anticancer immune response: indispensable for therapeutic success?J Clin Invest200811861991200118523649
   PubMed Web of Science ®Google Scholar
• RoselliMCeredaVdi BariMGEffects of conventional therapeutic interventions on the number and function of regulatory T cellsOncoimmunology2013210e2702524353914
   PubMed Web of Science ®Google Scholar
• JägerDJägerEKnuthAImmune responses to tumour antigens: implications for antigen specific immunotherapy of cancerJ Clin Pathol200154966967411533070
   PubMed Web of Science ®Google Scholar
• SchreiberRDOldLJSmythMJCancer immunoediting: integrating immunity’s roles in cancer suppression and promotionScience201133160241565157021436444
   PubMed Web of Science ®Google Scholar
• ApetohLGhiringhelliFTesniereAToll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNat Med20071391050105917704786
   PubMed Web of Science ®Google Scholar
• AndreFDieciMVDubskyPMolecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerClin Cancer Res2013191283323258741
   PubMed Web of Science ®Google Scholar
• BerkeGThe binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspectsAnnu Rev Immunol1994127357738011296
   PubMed Web of Science ®Google Scholar
• SegalNHParsonsDWPeggsKSEpitope landscape in breast and colorectal cancerCancer Res200868388989218245491
   PubMed Web of Science ®Google Scholar
• ZitvogelLKeppOKroemerGImmune parameters affecting the efficacy of chemotherapeutic regimensNat Rev Clin Oncol20118315116021364688
   PubMed Web of Science ®Google Scholar
• LiyanageUKMooreTTJooHGPrevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinomaJ Immunol200216952756276112193750
   PubMed Web of Science ®Google Scholar
• ViguierMLemaîtreFVerolaOFoxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cellsJ Immunol200417321444145315240741
   PubMed Web of Science ®Google Scholar
• MiyashitaMSasanoHTamakiKPrognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter studyBreast Cancer Res20151712426341640
   PubMed Web of Science ®Google Scholar
• IbrahimEMAl-FoheidiMEAl-MansourMMKazkazGAThe prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysisBreast Cancer Res Treat2014148346747625361613
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• WimberlyHBrownJRSchalperKPD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancerCancer Immunol Res20153432633225527356
   PubMed Web of Science ®Google Scholar
• GhebehHMohammedSAl-OmairAThe B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factorsNeoplasia20068319019816611412
   PubMed Web of Science ®Google Scholar
• MittendorfEAPhilipsAVMeric-BernstamFPD-L1 expression in triple-negative breast cancerCancer Immunol Res20142436137024764583
   PubMed Web of Science ®Google Scholar
• BeckersRKSelingerCIVilainRProgrammed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcomeHistopathology2016691253426588661
   PubMed Web of Science ®Google Scholar
• MengXHuangZTengFXingLYuJPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapyCancer Treat Rev2015411086887626589760
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFCheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• FerrisRLBlumenscheinGJrFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med2016375191856186727718784
   PubMed Web of Science ®Google Scholar
• CollinsLCColeKsMarottiJDHuRSchnittSJTamimiRMAndrogen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health StudyMod Pathol201124792493121552212
   PubMed Web of Science ®Google Scholar
• MrklićIPogorelićZCapkunVTomićSExpression of androgen receptors in triple negative breast carcinomasActa Histochem2013115434434823031358
   PubMed Web of Science ®Google Scholar
• ThikeAAYong-Zheng ChongLCheokPYLoss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancerMod Pathol201427335236023929266
   PubMed Web of Science ®Google Scholar
• SafarpourDPakneshanSTavassoliFAAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Am J Cancer Res201444353368 eCollection 201425057438
   PubMed Web of Science ®Google Scholar
• AgoffSNSwansonPELindenHHawesSELawtonTJAndrogen receptor expression in estrogen receptor–negative breast cancer. Immunohistochemical, clinical, and prognostic associationsAm J Clin Pathol2003120572573114608899
   PubMed Web of Science ®Google Scholar
• ParkSKooJParkHSExpression of androgen receptors in primary breast cancerAnn Oncol201021348849219887463
   PubMed Web of Science ®Google Scholar
• MasudaHBaggerlyKAWangYDifferential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesClin Cancer Res201319195533554023948975
   PubMed Web of Science ®Google Scholar
• CochraneDRBernalesSJacobsenBMRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res2014161R724451109
   PubMed Web of Science ®Google Scholar
• M.D. Anderson Cancer CenterPhase IIB neoadjuvant enzalutamide (ZT) plus taxol for androgen receptor (AR)-positive triple-negative breast cancer (AR+ TNBC) Available from: https://clinicaltrials.gov/ct2/show/NCT02689427. NLM identifier: NCT02689427Accessed December 8, 2017
   Google Scholar
• CeresaBPBahrSJrab7 activity affects epidermal growth factor: epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosomeJ Biol Chem200628121099110616282324
   PubMed Web of Science ®Google Scholar
• GuarneriVBarbieriEPiacentiniFPredictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysisInt J Biol Markers201025210411120544688
   PubMed Web of Science ®Google Scholar
• YadavBSChananaPJhambSBiomarkers in triple negative breast cancer: a reviewWorld J Clin Oncol20156625226326677438
   PubMedGoogle Scholar
• HanJSCaoDMolbergKHHormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomasAm J Clin Pathol2011135223023721228363
   PubMed Web of Science ®Google Scholar
• LangerødAZhaoHBorganØTP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancerBreast Cancer Res200793R3017504517
   PubMed Web of Science ®Google Scholar
• MillerLDSmedsJGeorgeJAn expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProc Natl Acad Sci U S A200510238135501355516141321
   PubMed Web of Science ®Google Scholar
• BiganzoliECoradiniDAmbrogiFp53 status identifies two subgroups of triple-negative breast cancers with distinct biological featuresJpn J Clin Oncol201141217217921199790
   PubMed Web of Science ®Google Scholar
• TurnerNMorettiESiclariOTargeting triple negative breast cancer: is p53 the answer?Cancer Treat Rev201339554155023321033
   PubMed Web of Science ®Google Scholar
• WalerychDNapoliMCollavinLDel SalGThe rebel angel: mutant p53 as the driving oncogene in breast cancerCarcinogenesis201233112007201722822097
   PubMed Web of Science ®Google Scholar
• BidardFCMatthieuMCCholletPp53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesAnn Oncol20081971261126518325917
   PubMed Web of Science ®Google Scholar
• LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128118250347
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMNüeschEImpact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsBreast Cancer Res Treat2011125114515621042932
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMBlohmerJUDefinition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesJ Clin Oncol201230151796180422508812
   PubMed Web of Science ®Google Scholar
• UntchMJackischCSchneeweissAGerman Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) InvestigatorsNab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialLancet Oncol201617334535626869049
   PubMed Web of Science ®Google Scholar
• GianniLMansuttiMAntonAETNA (evaluating treatment with neoadjuvant abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: a MICHELANGO studyJ Clin Oncol201634Suppl 15 abstract 502
   Web of Science ®Google Scholar
• KuwayamaTYamauchiHTakanoTPrimary analysis of a randomized phase II, multicenter trial: neoadjuvant weekly nab-paclitaxel 100 mg/m2 followed by FE100C compared with docetaxel 75 mg/m2 followed by FE100C for early breast cancer in JapanJ Clin Oncol201533Suppl 28 abstract 136
   Web of Science ®Google Scholar
• StefanssonOAVillanuevaAVidalAMartíLEstellerMBRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerEpigenetics20127111225122923069641
   PubMed Web of Science ®Google Scholar
• ChenXSYuanYGarfieldDHWuJYHuangOShenKWBoth carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysisPLoS One201499e10840525247558
   PubMed Web of Science ®Google Scholar
• HurleyJReisIMRodgersSEThe use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patientsBreast Cancer Res Treat2013138378379423542956
   PubMed Web of Science ®Google Scholar
• von MinckwitzGMartinMNeoadjuvant treatments for triple-negative breast cancer (TNBC)Ann Oncol201223Suppl 6vi35vi3923012300
   PubMedGoogle Scholar
• PetrelliFCoinuABorgonovoKThe value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysisBreast Cancer Res Treat2014144222323224557340
   PubMed Web of Science ®Google Scholar
• SikovWMDizonDSStrengerRFrequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group StudyJ Clin Oncol200927284693470019720916
   PubMed Web of Science ®Google Scholar
• ChenXSNieXQChenCMWeekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancerAnn Oncol201021596196720211870
   PubMed Web of Science ®Google Scholar
• RoyVPockajBAAllredJBA Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338Am J Clin Oncol201336654054422868240
   PubMed Web of Science ®Google Scholar
• ChangHRGlaspyJAllisonMADifferential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatmentCancer2010116184227423720549829
   PubMed Web of Science ®Google Scholar
• Campos GomezSCampos GomezKAGarcia GarcesMMorelosGHernandez AlvarezJNeoadjuvant carboplatin and docetaxel in locally advanced triple negative breast cancer: a Hispanic trialJ Clin Oncol201634Suppl 15 abstract e12554
   Web of Science ®Google Scholar
• von MinckwitzGSchneeweissALoiblSNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialLancet Oncol201415774775624794243
   PubMed Web of Science ®Google Scholar
• EnriquezDPoma NietoNFuentesHAGuerraHRuiz MendozaREGomezHLImproving pathological response in locally advanced triple negative breast cancer: comparison between CbD and AC-T regimensJ Clin Oncol201735Suppl 15 abstract 585
   Google Scholar
• KaklamaniVGJerussJSHughesEPhase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Breast Cancer Res Treat2015151362963826006067
   PubMed Web of Science ®Google Scholar
• Northwestern UniversityCarboplatin and eribulin mesylate in triple negative breast cancer patients Avalaible from: https://clinicaltrials.gov/ct2/show/NCT01372579. NLM identifier: NCT01372579Accessed June 1, 2011
   Google Scholar
• PetrelliFCabidduMCoinuAAdjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trialsBreast Cancer Res Treat2015151225125925917869
   PubMed Web of Science ®Google Scholar
• ReinischMAtasevenBKümmelSNeoadjuvant dose-dense and dose-intensified chemotherapy in breast cancer – review of the literatureBreast Care (Basel)2016111132027051390
   PubMed Web of Science ®Google Scholar
• HastakKAlliEFordJMSynergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine and cisplatinCancer Res201070207970798020798217
   PubMed Web of Science ®Google Scholar
• AlliESharmaVBSunderesakumarPFordJMDefective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of Poly(ADP-ribose) polymeraseCancer Res20096983589359619351835
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• BalmañaJTungNMIsakoffSJPhase I trial of olaparib in combi-nation with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumorsAnn Oncol20142581656166324827126
   PubMed Web of Science ®Google Scholar
• SomloGFrankelPHLuuTHEfficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancerJ Clin Oncol201331Suppl 15 abstract 1024
   Web of Science ®Google Scholar
• PahujaSBeumerJHApplemanLJA phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC)J Clin Oncol201533Suppl 15 abstract 1015
   Google Scholar
• KummarSChenAJiJPhase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasCancer Res201171175626563421795476
   PubMed Web of Science ®Google Scholar
• TelliMLJensenKCVinayakSPhase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105J Clin Oncol201533171895190125847929
   PubMed Web of Science ®Google Scholar
• RugoHSOlapadeODeMicheleAVeliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIALCancer Res20137324 Suppl Abstract nr S5-02
   PubMedGoogle Scholar
• GeyerCEO’ShaughnessyJUntchMPhase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC)J Clin Oncol201735Suppl 15 abstract 520
   Google Scholar
• M.D. Anderson Cancer CenterNeoadjuvant talazoparib for patients with a BRCA deleterious mutation Available from: https://clinical-trials.gov/ct2/show/NCT02282345. NLM Identifier: NCT02282345Accessed October 30, 2014
   Google Scholar
• GreenbergSRugoHSTriple-negative breast cancer: role of antiangiogenic agentsCancer J2010161333820164688
   PubMed Web of Science ®Google Scholar
• von MinckwitzGEidtmannHRezaiMGerman Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study GroupsNeoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerN Engl J Med2012366429930922276820
   PubMed Web of Science ®Google Scholar
• ThomssenCPiergaJYPritchardKIFirst-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA studyOncology201282421822722508241
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJRomieuGDiérasVByrtekMDuenneA-AMilesDMeta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC)Cancer Res20107024 Suppl P6-12-03
   Google Scholar
• EarlHMHillerLDunnJAARTemis InvestigatorsEfficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialLancet Oncol201516665666625975632
   PubMed Web of Science ®Google Scholar
• SikovWMBerryDAPerouCMImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)J Clin Oncol2015331132125092775
   PubMed Web of Science ®Google Scholar
• GolshanMCirrincioneCTCareyLAImpact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance)J Clin Oncol201533Suppl 15abstract 1007
   PubMed Web of Science ®Google Scholar
• GuarneriVDieciMVBisagniGPreoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be studyAnn Surg Oncol20152292881288725572687
   PubMed Web of Science ®Google Scholar
• KimHRJungKHImSAMulticentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)Ann Oncol20132461485149023380385
   PubMed Web of Science ®Google Scholar
• NahlehZABarlowWEHayesDFSWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerBreast Cancer Res Treat2016158348549527393622
   PubMed Web of Science ®Google Scholar
• MrózekELaymanRRamaswamyBPhase II trial of neo-adjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerClin Breast Cancer201414422823424703985
   PubMed Web of Science ®Google Scholar
• SchmidPParkYHMuñoz-CouseloEPembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173J Clin Oncol201735Suppl 15 abstract 556
   Google Scholar
• NandaRLiuMCYauCPembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2J Clin Oncol201735Suppl 15 abstract 506
   PubMedGoogle Scholar
• Fondazione MichelangeloNeoadjuvant therapy in TRIPle negative breast cancer with antiPDL1 (NeoTRIPaPDL1) Available from: https://clinicaltrials.gov/ct2/show/NCT02620280. NLM Identifier: NCT02620280Accessed November 3, 2015
   Google Scholar
• M.D. Anderson Cancer CenterTriple-negative first-line study: neoadjuvant trial of nab-paclitaxel and MPDL3280A, a Pdl-1 inhibitor in patients with triple negative breast cancer Avalaible from: https://clinicaltrials.gov/ct2/show/NCT02530489. NLM Identifier: NCT02530489Accessed August 19, 2015
   Google Scholar
• Yale UniversityNeoadjuvant MEDI4736 concomitant with weekly nab-paclitaxel and dose-dense AC for stage I–III triple negative breast cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02489448 NLM Identifier: NCT02489448Accessed July 1, 2015
   Google Scholar
• Merck Sharp & Dohme CorpSafety and efficacy study of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for participants with triple negative breast cancer (TNBC) (MK-3475-173/KEYNOTE 173) Available from: https://clinicaltrials.gov/show/NCT02622074. NLM Identifier: NCT02622074Accessed December 2, 2015
   Google Scholar
• National Cancer Institute (NCI)Pembrolizumab in treating patients with triple-negative breast cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02954874. NLM Identifier: NCT02954874Accessed November 3, 2016
   Google Scholar
• Pierfranco ConteIstitutoOncologico VenetoIRCCSAdjuvant treatment for high-risk triple negative breast cancer patients with the anti-PD-l1 antibody avelumab (A-Brave) Available from: https://clinicaltrials.gov/ct2/show/NCT02926196. NLM Identifier: NCT02926196Accessed October 5, 2016
   Google Scholar
• SenkusEKyriakidesSOhnoSESMO Guidelines CommitteePrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• DenduluriNSomerfieldMREisenASelection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) – negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice GuidelineJ Clin Oncol201634202416242727091714
   PubMed Web of Science ®Google Scholar